Company intelligence / Profile preview

InventisBio

Shanghai/Pudong New Area, Shanghai, Chinainventisbio.com ↗

Ownership: Private
Employees: ~221
Development stage: Commercial

Overview

InventisBio has two drugs approved in China and three additional candidates in clinical trials. The most advanced program is in Phase 3 registration trials. Notably, their KRAS G12C inhibitor "Garsorasib" received market authorization from the NMPA of China for NSCLC and has been added to the Breakthrough Therapy Designation Program for new indications. Their TYK2 inhibitor D2570 showed positive results in a Phase 2 study for moderate to severe plaque psoriasis.

Therapeutic areas: OncologyImmunologyMetabolic Disorders
Modalities: Small molecules
Industry: Biotech

Drug pipeline

7 assets

taragarestrant

6 more assets in the full pipeline.

Request access →

Partnerships

Betta Pharmaceuticals collaboration agreement

Beyond the preview

Go deeper on InventisBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on InventisBio.

Explore the full profile